← All educational resources

The Neurotransmitter Map: Why the Same Chemical Does Different Things in Different Places

2026-11-16

Same post, two depths. Switch any time; the research version has the enzyme names, lab markers, and doses. Written from a research and education perspective: a model of what may be going on and what the published literature suggests would address it if the model is right, not medical advice or a treatment plan.

People talk about dopamine as if it were one thing: the reward chemical, the motivation chemical, the thing phones hijack. Serotonin is "the happy chemical." GABA is "the calm one." None of that is wrong, exactly, but it is the kind of wrong that leads people to take a supplement for one problem and create another.

Here is the idea this whole page rests on. A neurotransmitter is not a mood. It is a signal, and what the signal means depends entirely on which wire it is sent down. Dopamine released in one part of the brain makes you want things. The same dopamine, released two centimeters away, lets you move your hand smoothly. In a third place it turns off a hormone in your pituitary. In your kidney it makes you pee out salt. Same molecule, four jobs.

That matters because almost nothing you can take, prescription or supplement, works in only one place. L-DOPA raises dopamine everywhere. An SSRI raises serotonin everywhere, including the 95 percent of your serotonin that lives in your gut. A benzodiazepine strengthens GABA everywhere, which is why it calms anxiety and also makes you forget the evening. If you understand the map, the side effects stop being mysterious and the right lever gets easier to pick.

This page is a map, not a prescription. It is written from a research and education perspective: here is what each chemical does in each place, what too much and too little look like there, and what the literature says about what moves each one. Anything you consider trying goes to your own clinician, especially anything that touches a prescription you already take.

How to read this page

Each neurotransmitter gets a section. Inside each section, the pathways (the wires) get a short description of what the signal does there, what too much looks like, what too little looks like, and what moves it. At the end there is a section on the raw materials, because every one of these chemicals is built from food with the help of iron, B6, folate, copper, magnesium, and a few others, and running low on a cofactor is the most common way a person ends up "low" in one of them without any gene or drug involved.

One more thing before the map. Because most levers act everywhere, the question to ask about any compound is not "does it raise dopamine" but "which pathway do I want more signal in, and what will the other three do with the extra."

Dopamine

Dopamine is made from the amino acid tyrosine in a two-step process that needs iron and a helper molecule called BH4 (which methylation keeps topped up). It is released from two main clusters of cells in the midbrain and from one in the hypothalamus, and each cluster sends its wires somewhere different.

The mesolimbic pathway: wanting

The wire runs from the midbrain to the nucleus accumbens, the brain's "go get it" center. Dopamine here is not pleasure; it is anticipation. It fires when something is better than expected and marks it as worth pursuing again.

  • Too much here: craving, compulsive pursuit, gambling, binge behavior, and at the far end, the suspiciousness and hearing-things of psychosis. Stimulants, L-DOPA, and dopamine agonists can all tip this pathway over; so can sleep deprivation.
  • Too little here: nothing feels worth doing. Anhedonia, flat motivation, the "I know I should but I cannot make myself" of depression and burnout. Not sadness exactly; absence of pull.
  • What moves it: stimulants (amphetamine, methylphenidate) raise it sharply; bupropion raises it gently; antipsychotics block the receptors (that is the whole point of them for psychosis). L-tyrosine and mucuna (natural L-DOPA) raise it, along with every other dopamine pathway. Caffeine and nicotine raise it indirectly. Rhodiola and ginseng have modest research on motivation and fatigue that likely runs through here.

The mesocortical pathway: focus and planning

The wire runs from the midbrain to the prefrontal cortex, the part of the brain that holds a plan in mind, filters distraction, and decides what to do next. Dopamine here works on a curve: too little and you cannot focus, too much and you cannot focus either, because everything feels equally important.

  • Too much here: racing thoughts, scattered attention, overthinking, anxiety, the jittery over-caffeinated state.
  • Too little here: brain fog, trouble starting tasks, poor working memory, the executive-function picture of ADHD, and the flat, withdrawn "negative symptoms" of schizophrenia (which antipsychotics can make worse, because they block dopamine here too).
  • What moves it: the same stimulants, but the dose that helps focus is lower than the dose that drives craving; this is why ADHD medication is titrated carefully. Guanfacine and clonidine act on norepinephrine receptors in the same region and improve focus without the mesolimbic push. The COMT gene variant matters most here: the slow version (met/met) keeps prefrontal dopamine higher, so those people often feel worse on stimulants and better with calming support; the fast version (val/val) clears it quickly and tends to do well with more. The neurotransmitters here report covers COMT and the others on this page.

The nigrostriatal pathway: movement

The wire runs from the substantia nigra to the striatum, and dopamine here is the lubricant for smooth, automatic movement. It also balances against acetylcholine in the same spot, like two kids on a seesaw.

  • Too much here: involuntary movements: tics, the writhing movements (dyskinesia) that appear after years of L-DOPA, restlessness.
  • Too little here: stiffness, slowness, tremor, shuffling, the mask-like face of Parkinson's disease; and, at a milder level, the drug-induced parkinsonism that antipsychotics and the anti-nausea drug metoclopramide cause. Restless legs lives here too, driven by low iron in the exact cells that make this dopamine.
  • What moves it: L-DOPA (with carbidopa so it reaches the brain) is the gold standard; dopamine agonists (pramipexole, ropinirole) stimulate the receptors directly; MAO-B inhibitors (selegiline, rasagiline) slow the breakdown. Iron repletion is the lever for restless legs (ferritin over 75; see the ferritin post here). Anticholinergic drugs tip the seesaw the other way and reduce tremor. Mucuna raises it like L-DOPA does, with the same long-term concerns.

The tuberoinfundibular pathway: prolactin

A short wire from the hypothalamus to the pituitary. Dopamine here has one job: keep prolactin switched off.

  • Too much here: prolactin drops; usually silent.
  • Too little here (or receptors blocked): prolactin rises, which causes missed periods, milk production when not nursing, low libido, breast tenderness in men, and over years, bone loss. This is the classic side effect of risperidone and other antipsychotics, and of metoclopramide and domperidone.
  • What moves it: dopamine agonists (cabergoline, bromocriptine) lower prolactin so reliably that they are the treatment for prolactin-secreting tumors. Vitamin B6 at modest doses lowers prolactin slightly in some studies. Vitex (chasteberry) acts as a weak dopamine agonist here and is the main reason it has any effect on cycles.

Dopamine outside the brain

The dopamine that circulates in blood does not enter the brain. It is made in the kidney, the gut, and nerve endings, and it has its own jobs: the kidney uses it to dump sodium (which is why L-DOPA can lower blood pressure and cause nausea), the gut uses it to slow motility, and it is the raw material for norepinephrine in every sympathetic nerve. Low dopamine-to-norepinephrine conversion (the copper and vitamin C enzyme DBH) shows up in POTS as a specific pattern; see the pots post here.

Serotonin

Serotonin is made from tryptophan in two steps, the first needing iron and BH4, the second needing vitamin B6. The brain's serotonin comes from a small cluster of cells in the brainstem (the raphe nuclei) that send wires everywhere. But 90 to 95 percent of the serotonin in your body is made in the gut lining, and gut serotonin cannot cross into the brain. The two are separate economies that share one raw material.

Cortex and limbic system: mood and patience

Serotonin here is less a happiness signal than a tolerance signal. It raises the threshold for frustration, impulsivity, and aggression, and it dampens the alarm system (the amygdala).

  • Too much here: emotional flatness, apathy, blunted libido, and at the extreme (usually from combining drugs) the agitation, sweating, high temperature, and muscle twitching of serotonin syndrome.
  • Too little here: irritability, low frustration tolerance, impulsivity, rumination, low mood, seasonal dips, and the carb cravings of winter (the brain uses carbohydrate to push tryptophan across).
  • What moves it: SSRIs block the pump that recycles serotonin, raising it in the gap between cells; they take weeks because the real change is receptor adaptation. 5-HTP and tryptophan feed the pipeline; they raise serotonin in the gut and the body as well as the brain, and combining them with an SSRI is a real risk. Saffron has several decent trials matching SSRIs in mild depression. St. John's wort works like a weak SSRI and interacts with many drugs. Bright light in the morning and exercise both raise serotonin signaling in this region.

Brainstem: sleep, breathing, body temperature

The raphe cells that project downward help set the sleep-wake rhythm (serotonin is the raw material for melatonin), control breathing drive in response to carbon dioxide, and regulate body temperature.

  • Too much here: hyperthermia in serotonin syndrome; vivid dreams and disrupted sleep architecture on SSRIs.
  • Too little here: poor sleep consolidation, low melatonin, and in infants, the sudden infant death literature points at brainstem serotonin.
  • What moves it: melatonin itself for the downstream effect; tryptophan at night; the same SSRIs. Trazodone, at low doses, is used for sleep largely through blocking a particular serotonin receptor rather than raising serotonin.

Spinal cord: pain volume

Serotonin coming down from the brainstem into the spinal cord turns down the volume on incoming pain signals, alongside norepinephrine.

  • Too little here: widespread pain amplification, the "everything hurts" of fibromyalgia, where this descending brake is measurably weak. See the fibromyalgia post here.
  • What moves it: duloxetine and milnacipran (SNRIs) are approved for fibromyalgia for exactly this reason: they raise both serotonin and norepinephrine in the descending pathway. Low-dose amitriptyline works the same way. Exercise and sleep repair strengthen the brake over time.

Gut: motility, secretion, nausea

Here serotonin is a local hormone. It is released by the gut lining in response to food and stretch, triggers the peristaltic wave, drives secretion, and signals nausea to the brainstem through the vagus nerve.

  • Too much here: diarrhea, cramping, nausea; the GI side effects in the first weeks of an SSRI; the flushing and diarrhea of carcinoid tumors; the gut symptoms of SIBO, where bacteria stimulate serotonin release.
  • Too little here: constipation, slow transit, poor gut motility.
  • What moves it: ondansetron blocks the nausea receptor (5-HT3) and is also used for diarrhea-type IBS. Prucalopride stimulates the motility receptor (5-HT4) for constipation. Any serotonin precursor raises gut serotonin first. Probiotics and fiber change the gut's serotonin output through the microbiome, which is one reason gut work changes mood; the SIBO post here covers that.

Blood and bone

Platelets carry serotonin and release it to constrict vessels and help clotting; this is why SSRIs raise bleeding risk slightly and why migraine drugs (triptans) are serotonin receptor agonists that narrow blood vessels. Circulating serotonin also tells bone-building cells to slow down, which is part of why long-term SSRI use is associated with lower bone density.

GABA and glutamate

These two are the brain's brake and accelerator, and they are made from each other: glutamate is turned into GABA by an enzyme that needs vitamin B6 (as P5P), magnesium, and zinc. Glutamate is the main excitatory signal in the brain; GABA is the main inhibitory one. Almost every sedative, anti-anxiety, anti-seizure, and sleep drug works on one of them.

GABA does not cross from the blood into the brain in any meaningful amount, which is why GABA capsules have little direct brain effect (though there is evidence they act on the gut's own nervous system and the vagus nerve).

Cortex: the seizure threshold and overstimulation

GABA in the cortex keeps excitation in check. The balance between the two sets the seizure threshold and how much sensory input feels like too much.

  • Too much GABA (or too little glutamate): sedation, slowed thinking, poor memory formation, the hangover of sleeping pills.
  • Too little GABA (or too much glutamate): sensory overload, light and sound sensitivity, migraine, seizures at the extreme, and the brain fog and "wired" feeling of excitotoxicity.
  • What moves it: anti-seizure drugs (valproate, gabapentin, pregabalin, topiramate) each raise GABA tone or lower glutamate release in a different way. Magnesium blocks the main glutamate receptor (NMDA) and is the most useful nutrient lever for the overstimulated brain; taurine and glycine both act on inhibitory receptors; theanine raises GABA and lowers glutamate modestly. Ketamine blocks NMDA briefly and is now used for severe depression through a rebound growth effect that follows.

Amygdala: anxiety and threat

The amygdala is the alarm. GABA keeps the alarm from firing at every noise.

  • Too little GABA here: anxiety, panic, hypervigilance, the sense of threat without a threat.
  • Too much here: emotional numbing; disinhibition on alcohol or benzodiazepines (the alarm is off, so judgment goes with it).
  • What moves it: benzodiazepines (and the "Z" sleep drugs) make GABA work harder at its receptor and act everywhere, which is why they relieve anxiety, induce sleep, relax muscles, and impair memory all at once, and why stopping them abruptly after months can cause rebound anxiety and seizures. Among plants, kava has real anti-anxiety trial data and a liver caution; lemon balm, passionflower, and valerian are milder; apigenin (from chamomile) binds the benzodiazepine site weakly, which is why this site prefers it at night over quercetin for sleep. Phenibut, sold online, is a GABA-B drug with a benzodiazepine-like dependence problem and belongs in the "do not" column. Alcohol is a GABA drug with a glutamate rebound, which is the whole story of the hangover and the 3 am wake-up.

Thalamus: the sleep switch and sensory gate

GABA in the thalamus closes the gate on sensory input at sleep onset and generates sleep spindles.

  • Too little: can't fall asleep, every sound comes through, light sleep.
  • What moves it: most sleep drugs act here; melatonin and magnesium work upstream; consistent darkness and temperature drop do more than people expect. The 3am post here covers the histamine side of the same switch.

Spinal cord and muscle: tone and spasm

GABA and glycine in the spinal cord keep muscle tone in check.

  • Too little: muscle tightness, spasm, the exaggerated reflexes of stiff-person syndrome (where antibodies attack the GABA-making enzyme).
  • What moves it: baclofen (GABA-B) for spasticity; magnesium for cramps and tightness; glycine, which is also the inhibitory transmitter in the cord, and which collagen peptides supply in quantity.

GABA outside the brain

The pancreas makes GABA in its insulin-producing cells, where it protects them. The gut makes it and so do several gut bacteria (Lactobacillus and Bifidobacterium strains), which may be how probiotics and the vagus nerve influence anxiety without any GABA crossing into the brain.

Acetylcholine

Acetylcholine is made from choline (the nutrient in eggs and liver) and acetyl-CoA, the energy intermediate. It is the oldest transmitter in the body and has two completely different careers: in the brain it runs attention and memory, and outside the brain it runs the "rest and digest" nervous system and every voluntary muscle.

Basal forebrain to cortex and hippocampus: memory and attention

A cluster of cells at the base of the brain sends acetylcholine to the whole cortex. It sharpens attention, allows new memories to be laid down, and turns up the signal-to-noise on what you are paying attention to.

  • Too little here: poor memory formation, confusion, inattention. The drugs that block acetylcholine (diphenhydramine, oxybutynin, older antidepressants, many bladder and nausea drugs) cause exactly this, and a high lifetime "anticholinergic burden" is associated with dementia risk. Alzheimer's disease destroys these cells early.
  • Too much here: rare on its own; nausea, vivid dreams, tearing, and cramps if cholinesterase inhibitors are overdone.
  • What moves it: donepezil and the other Alzheimer's drugs block the enzyme that breaks acetylcholine down. Huperzine A does the same thing and is sold as a supplement. Choline itself, as CDP-choline (citicoline) or alpha-GPC, feeds the pipeline and has modest trial support for attention and recovery after stroke. Bacopa and lion's mane have small trials on memory with different mechanisms. The most under-rated lever is stopping anticholinergic drugs that are no longer needed, with the prescriber; the medications table here lists them.

Striatum: the other side of the seesaw

Acetylcholine in the striatum balances dopamine for movement.

  • Too much relative to dopamine: tremor and stiffness; this is why anticholinergic drugs (benztropine) treat drug-induced parkinsonism.
  • Too little relative to dopamine: tics and involuntary movements.

Brainstem: REM sleep

Acetylcholine switches on REM sleep (dreaming sleep). Cholinesterase inhibitors cause vivid dreams; anticholinergics suppress REM; depression comes with early, intense REM, which is one reason cholinergic tone is studied in mood.

Outside the brain: the vagus nerve and rest-and-digest

This is the parasympathetic nervous system. Acetylcholine from the vagus nerve slows the heart, stimulates digestion, triggers stomach acid and enzymes, moves the bowel, empties the bladder, constricts the pupil, and makes saliva and tears.

  • Too little (low vagal tone): dry mouth and eyes, constipation, slow stomach emptying, fast resting heart rate, low heart rate variability, poor digestion. This is the picture in POTS and in anyone on anticholinergic drugs; it is also why those drugs are prescribed on purpose for overactive bladder, drooling, and IBS cramping.
  • Too much: the cholinergic crisis of nerve agents and organophosphate pesticides: drooling, tearing, diarrhea, slow heart, pinpoint pupils. Rare outside poisoning.
  • What moves it: slow breathing (four in, six out), cold water on the face, humming, and gargling all raise vagal tone measurably; this is the "retrain the autopilot" piece of the pots post here. Choline supports the supply. Bethanechol is the prescription that stimulates these receptors for bladder and stomach emptying. The vagus nerve also has an anti-inflammatory job: acetylcholine tells immune cells in the spleen to make less TNF, which is why vagus nerve stimulation is being trialled for rheumatoid arthritis and Crohn's.

Muscle: the neuromuscular junction

Every voluntary movement happens because a motor nerve releases acetylcholine onto a muscle.

  • Too little signal: the fatigable weakness of myasthenia gravis (antibodies block the receptor), where cholinesterase inhibitors (pyridostigmine) are the treatment; pyridostigmine is also used off-label in POTS for the same reason, to raise acetylcholine at autonomic ganglia.
  • Too much: fasciculations, cramps; botulinum toxin works by stopping release entirely.

Norepinephrine

Norepinephrine is made from dopamine by DBH, an enzyme that needs copper and vitamin C. In the brain it comes almost entirely from one small cluster, the locus coeruleus; outside the brain it is the main transmitter of the sympathetic ("fight or flight") nerves.

Locus coeruleus to the whole brain: arousal and attention

  • Too much: anxiety, insomnia, hypervigilance, startle, racing heart on waking, the feel of a panic attack or of too much stimulant.
  • Too little: low arousal, inattention, poor alertness, the "cannot wake up" fatigue.
  • What moves it: atomoxetine and SNRIs raise it; stimulants raise it along with dopamine; clonidine and guanfacine lower its release (which is why they treat ADHD, tics, hypertension, and the nightmares of PTSD); prazosin blocks its receptors for PTSD nightmares; beta-blockers block its downstream effects on heart and tremor. Low-dose propranolol is the "stage fright" drug for exactly this reason.

Sympathetic nerves: the body's accelerator

Norepinephrine here raises heart rate and blood pressure, constricts blood vessels, dilates pupils and airways, and shunts blood to muscle.

  • Too much: the hyperadrenergic form of POTS (standing norepinephrine very high), sweating, tremor, high blood pressure spikes; the surge of a pheochromocytoma.
  • Too little: low blood pressure on standing, fainting, the inability to constrict vessels in neuropathic POTS, and in the rare genetic DBH deficiency, severe orthostatic hypotension with normal mental alertness, because dopamine piles up and norepinephrine never gets made.
  • What moves it: midodrine directly stimulates the vessel receptors; droxidopa is a norepinephrine precursor used in autonomic failure; beta-blockers and clonidine tone it down. Copper and vitamin C are the DBH cofactors; copper deficiency from zinc supplementation lowers the whole conversion. The pots post here walks through the three POTS subtypes along exactly these lines.

Histamine

Histamine in the brain is a wake signal, released from a single cluster in the hypothalamus that fires only when you are awake. Histamine outside the brain is a mast cell and gut signal. This site has the 3am post here on the sleep side of it and the mast cell post here on the body side; the short version for the map:

  • Too much brain histamine: insomnia, the wired 3 am wake-up, anxiety, itch.
  • Too little: drowsiness (every first-generation antihistamine that crosses into the brain causes it) and, in the long run, the dementia association with those drugs.
  • What moves it: H1 antihistamines that cross into the brain (diphenhydramine, hydroxyzine, doxepin) sedate; the newer ones (cetirizine, fexofenadine) mostly do not. Mirtazapine's sleepiness is largely histamine blockade. Pitolisant does the opposite, raising brain histamine to treat narcolepsy. Clearance depends on the HNMT enzyme (methylation) in the brain and DAO (copper, B6) in the gut, which is where the diet and methylation levers come in.

The raw materials: where "low" usually comes from

Most people who feel low in one of these chemicals are not low in the chemical. They are low in something it is made from, or something that clears it. The genes table here and the nutrient guide here go deeper; here is the map version.

Transmitter Built from Needs Cleared by
Dopamine Tyrosine Iron, BH4 (folate and methylation keep it recycled), B6 COMT (needs SAMe and magnesium), MAO-B (needs riboflavin)
Norepinephrine Dopamine Copper, vitamin C COMT, MAO-A
Serotonin Tryptophan Iron, BH4, B6; carbohydrate helps entry into the brain MAO-A (riboflavin)
GABA Glutamate B6 (as P5P), magnesium, zinc GABA transaminase
Acetylcholine Choline + acetyl-CoA B5, energy supply, choline from eggs, liver, or supplement Cholinesterase
Histamine Histidine B6 HNMT (SAMe), DAO (copper, B6)

A few patterns fall out of that table:

  • Iron sits under dopamine, serotonin, and norepinephrine. Low ferritin looks like low dopamine (restless legs, fatigue, inattention) and low serotonin (low mood) at the same time.
  • B6 sits under serotonin, GABA, dopamine, and histamine clearance. The P5P form skips the activation step that some people cannot do well.
  • Copper sits under norepinephrine and histamine clearance. Zinc supplements without copper quietly take it away.
  • Methylation (folate, B12, SAMe) sits under BH4 recycling and under COMT and HNMT clearance. This is why methylfolate can shift mood and histamine symptoms quickly in people whose methylation is stretched, and why the same supplement makes a slow-COMT person feel over-stimulated.
  • Magnesium blocks the glutamate receptor and powers COMT. It is the single most used nutrient on this site for a reason.

Precursor loading: the thing to be careful with

Tyrosine, 5-HTP, tryptophan, mucuna, and choline all work by pushing more raw material into the pipeline. Three cautions, from the research rather than from caution for its own sake:

  1. The pipeline is shared. Tyrosine and tryptophan compete for the same transporter into the brain; loading one lowers the other. Taking 5-HTP alone for months lowers dopamine; taking tyrosine alone lowers serotonin. The older practitioner habit of pairing them in a ratio is not well studied but the competition behind it is.
  2. Precursors raise the transmitter everywhere. 5-HTP raises gut serotonin before brain serotonin; mucuna raises nigrostriatal and mesolimbic dopamine together.
  3. Precursors plus a drug that blocks reuptake or breakdown is where serotonin syndrome and hypertensive crises come from. 5-HTP with an SSRI, tyrosine with an MAO inhibitor, and St. John's wort with almost anything serotonergic are the combinations to take to a clinician before, not after.

The experimental column

Because people ask: ketamine and esketamine (glutamate, NMDA blockade, now approved for resistant depression under supervision), psilocybin (serotonin 5-HT2A, in late-stage trials for depression, not legal in most places), and vagus nerve stimulation (acetylcholine, approved for epilepsy and depression, in trials for inflammation) are the three with real evidence. Compounds sold online as "nootropics" with Russian or animal-only data (phenibut, bromantane, and the many peptides) do not have the trials to put them on a map, and phenibut specifically has a dependence problem serious enough that I would not touch it.

What this map is for

If you take one thing from this page, make it this: before raising or lowering any of these chemicals, name the pathway. "I want more dopamine" is not a target. "I want more prefrontal dopamine without more striatal and mesolimbic dopamine" is, and it points at different levers (COMT status, iron, sleep, guanfacine-type approaches through a clinician) than "I want more motivation" does. The same discipline applies to serotonin (brain or gut?), GABA (which receptor, which region?), and acetylcholine (brain or vagus?). The neurotransmitters here report maps the genes that set each person's starting point; the lab guide here covers the organic acids that show which pipelines are running short.

Educational content written from a research perspective, not medical advice. I am a PhD scientist, not a physician, and I do not diagnose, treat, cure, or prevent disease. Nothing here is a reason to start, stop, or combine a medication; those decisions belong with your prescriber, and the combinations named above carry real risk.

The organizing principle

A neurotransmitter's effect is determined by the projection it travels in, the receptor subtypes expressed at the target, and the local clearance machinery, not by the molecule itself. Dopamine is motivational in the ventral striatum, cognitive in the prefrontal cortex, motor in the dorsal striatum, endocrine at the median eminence, and natriuretic in the proximal tubule. Nearly every pharmacological and nutritional lever is systemic, so the clinical questions are which projection is the target, which projections carry the collateral effect, and whether receptor selectivity or regional expression can be used to separate them. This page lays out each system by projection, the recognized hypo- and hyperfunction syndromes, and the agents that act on each, with the evidence grade where it matters. It is a research and education resource, not treatment guidance; prescribing decisions are the treating clinician's.

Dopamine

Synthesis and clearance. Tyrosine, by tyrosine hydroxylase (TH; Fe2+ and tetrahydrobiopterin dependent, rate limiting), to L-DOPA, by aromatic L-amino acid decarboxylase (AADC; PLP dependent), to dopamine. BH4 is regenerated by DHPR and QDPR with NADH and is sensitive to folate and oxidative status. Clearance is by DAT reuptake, MAO-B (FAD) and COMT (SAMe, Mg2+). COMT Val158Met (rs4680) produces a three- to four-fold difference in enzyme activity; Met/Met carriers have higher tonic prefrontal dopamine. Dopaminergic cell groups: A9 (substantia nigra pars compacta, SNc), A10 (ventral tegmental area, VTA), A12 (arcuate nucleus, tuberoinfundibular), A11 (diencephalospinal), and peripheral sources (renal proximal tubule, enteric neurons, sympathetic terminals as the norepinephrine precursor).

Mesolimbic (VTA to nucleus accumbens, amygdala, hippocampus)

Function: reward prediction error, incentive salience, reinforcement learning. Phasic burst firing encodes "better than expected."

  • Hyperfunction: craving, compulsive behavior, impulse-control disorders (dopamine agonist therapy produces pathological gambling and hypersexuality in roughly 14 percent of Parkinson's patients), positive symptoms of psychosis (the dopamine hypothesis is best supported for presynaptic striatal hyperdopaminergia on PET), stimulant-induced psychosis, mania.
  • Hypofunction: anhedonia, amotivation, the reward-deficit phenotype of depression and withdrawal states, negative symptoms.
  • Agents: amphetamine (DAT reversal, VMAT2), methylphenidate (DAT and NET blockade), bupropion (weak DAT and NET inhibition), D2 antagonists and partial agonists (haloperidol, risperidone, aripiprazole), pramipexole (D3-preferring agonist, trialled in depression). Precursors (L-tyrosine, Mucuna pruriens as L-DOPA) raise all projections. Caffeine (A2A antagonism disinhibits D2 signaling) and nicotine (nAChR on VTA neurons) act indirectly. Rhodiola rosea and Panax ginseng have small trials in fatigue and depression with mixed quality.

Mesocortical (VTA to prefrontal cortex)

Function: working memory, set-shifting, attentional filtering, via D1 receptors on pyramidal neurons and interneurons. The dose-response is an inverted U: D1 stimulation improves prefrontal function up to an optimum and degrades it beyond.

  • Hyperfunction: distractibility, anxiety, perseveration, over-arousal; stimulant overdose; Met/Met COMT carriers under stress.
  • Hypofunction: executive dysfunction, poor working memory, ADHD (the DAT1 and DRD4 associations are modest), negative and cognitive symptoms of schizophrenia (D2 antagonists can worsen these through prefrontal blockade), apathy.
  • Agents: stimulants at low doses preferentially raise prefrontal catecholamines (NET-mediated dopamine clearance in cortex means NET inhibitors such as atomoxetine raise prefrontal dopamine without striatal effect); guanfacine (alpha-2A agonist) and clonidine strengthen prefrontal network function post-synaptically; modafinil (weak DAT inhibition, orexinergic). COMT inhibitors (tolcapone, entacapone) raise cortical dopamine more than striatal because DAT density is low in cortex; tolcapone improves working memory in Val/Val carriers and impairs it in Met/Met in small studies. The neurotransmitters here report covers COMT, DRD2, DRD4, DAT1, MAOA and MAOB.

Nigrostriatal (SNc to dorsal striatum: caudate and putamen)

Function: initiation and fluency of movement through the direct (D1) and indirect (D2) basal ganglia pathways; balanced against striatal cholinergic interneurons.

  • Hyperfunction: chorea, tics, L-DOPA-induced dyskinesia (pulsatile D1 stimulation with sensitized receptors), tardive dyskinesia (D2 supersensitivity after chronic blockade).
  • Hypofunction: bradykinesia, rigidity, rest tremor, hypomimia (Parkinson's disease, roughly 60 to 80 percent of SNc neurons lost at diagnosis), drug-induced parkinsonism (antipsychotics, metoclopramide, prochlorperazine, valproate, flunarizine), restless legs syndrome (brain iron deficiency in A11 and SNc, with reduced TH activity and D2 density; ferritin target over 75 ng/mL; see the ferritin post here).
  • Agents: carbidopa/levodopa, dopamine agonists (pramipexole, ropinirole, rotigotine), MAO-B inhibitors (selegiline, rasagiline, safinamide), COMT inhibitors as adjuncts, amantadine (NMDA antagonism for dyskinesia), anticholinergics (benztropine, trihexyphenidyl) for tremor by rebalancing against acetylcholine, VMAT2 inhibitors (tetrabenazine, valbenazine) for tardive dyskinesia and chorea. Iron repletion for RLS; alpha-2-delta ligands (gabapentin enacarbil, pregabalin) are now first line over agonists because of augmentation. Mucuna pruriens (standardized L-DOPA) has small trials showing equivalence to carbidopa/levodopa over hours, with the same long-term concerns.

Tuberoinfundibular (arcuate nucleus to median eminence)

Function: tonic D2-mediated inhibition of lactotroph prolactin secretion.

  • Hyperfunction: hypoprolactinemia (rarely symptomatic).
  • Hypofunction or blockade: hyperprolactinemia with galactorrhea, amenorrhea, hypogonadism, gynecomastia, reduced bone density. Risperidone, paliperidone, amisulpride, haloperidol, metoclopramide, and domperidone (which does not cross the blood-brain barrier but acts on the median eminence outside it) are the common causes. Aripiprazole's partial agonism lowers prolactin.
  • Agents: cabergoline and bromocriptine (D2 agonists) for prolactinoma; pyridoxine lowers prolactin modestly in some studies; Vitex agnus-castus is a weak D2 agonist with small trials in cyclic mastalgia and PMS.

Diencephalospinal (A11) and peripheral dopamine

A11 provides spinal dopamine with antinociceptive and motor modulation; its iron-dependent dysfunction is the leading RLS model. Peripheral dopamine does not cross the blood-brain barrier. Renal D1 receptors promote natriuresis and vasodilation (fenoldopam); gut D2 receptors slow motility (domperidone and metoclopramide act here as prokinetics); dopamine at sympathetic terminals is the DBH substrate. Impaired DBH activity (copper or ascorbate insufficiency, DBH variants) raises the plasma dopamine to norepinephrine ratio, a pattern relevant to neuropathic POTS and discussed in the pots post here.

Serotonin

Synthesis and clearance. Tryptophan, by tryptophan hydroxylase (TPH1 peripheral, TPH2 central; Fe2+ and BH4 dependent, rate limiting), to 5-hydroxytryptophan, by AADC (PLP) to serotonin. Clearance by SERT (SLC6A4) and MAO-A (FAD). About 90 to 95 percent of body serotonin is enterochromaffin; peripheral serotonin does not cross the blood-brain barrier. Tryptophan competes with other large neutral amino acids for the LAT1 transporter; insulin lowers competing amino acids, which is the carbohydrate-serotonin link. Tryptophan is also diverted to kynurenine by IDO (inflammation) and TDO (cortisol), which lowers substrate for serotonin during inflammatory states. Receptor families: 5-HT1A (autoreceptor in raphe, postsynaptic anxiolytic), 5-HT1B/1D (vascular, triptan targets), 5-HT2A (cortical, psychedelic target, platelet), 5-HT2C (appetite, mood), 5-HT3 (ionotropic, nausea, gut), 5-HT4 (gut motility, memory), 5-HT6, 5-HT7 (circadian, mood).

Raphe to cortex and limbic system

Function: regulation of mood, impulse control, aggression threshold, amygdala reactivity.

  • Hyperfunction: emotional blunting and apathy on SSRIs, sexual dysfunction (5-HT2 and 5-HT3 mediated), serotonin syndrome (clonus, hyperreflexia, hyperthermia, agitation; Hunter criteria), usually from combinations (SSRI plus MAOI, tramadol, linezolid, dextromethorphan, 5-HTP, St. John's wort).
  • Hypofunction: irritability, impulsive aggression, rumination, seasonal affective disorder, carbohydrate craving, low frustration tolerance. The tryptophan-depletion paradigm reliably induces relapse in remitted SSRI responders.
  • Agents: SSRIs, SNRIs, vortioxetine (multimodal), mirtazapine (alpha-2 antagonism increases serotonin and norepinephrine release; 5-HT2 and H1 blockade), buspirone (5-HT1A partial agonist), psilocybin (5-HT2A agonist; phase 2 and 3 trials in major depression with large but variable effect sizes under supervised conditions). Precursors: L-tryptophan 1 to 3 g and 5-HTP 50 to 300 mg (bypasses TPH, raises peripheral serotonin first; contraindicated with serotonergic drugs). Saffron 30 mg daily matched fluoxetine and imipramine in several small Iranian trials and a 2019 meta-analysis supports it in mild to moderate depression. Hypericum (St. John's wort) is a weak SERT and NET inhibitor with CYP3A4 and P-glycoprotein induction. Bright light therapy and aerobic exercise raise serotonergic tone and have trial support in seasonal and non-seasonal depression.

Raphe to brainstem and hypothalamus

Function: sleep-wake regulation (serotonin promotes wakefulness and is the melatonin precursor through AANAT and ASMT in the pineal), central chemoreception (medullary raphe serotonergic neurons sense CO2 and drive ventilation; their deficiency is implicated in sudden infant death), thermoregulation.

  • Hyperfunction: hyperthermia in serotonin syndrome; REM suppression and vivid dreaming on SSRIs.
  • Hypofunction: low melatonin output, fragmented sleep, blunted hypercapnic response.
  • Agents: melatonin (downstream), tryptophan at night, agomelatine (MT1/MT2 agonist, 5-HT2C antagonist), trazodone (5-HT2A antagonism and H1 blockade at low doses).

Descending raphe-spinal projection

Function: descending pain modulation with norepinephrine, gating dorsal horn transmission; also contributes to RLS and spinal motor tone.

  • Hypofunction: central sensitization, widespread pain, reduced conditioned pain modulation, as in fibromyalgia (see the fibromyalgia post here).
  • Agents: duloxetine and milnacipran (FDA approved for fibromyalgia), amitriptyline and nortriptyline, tramadol (serotonergic plus opioid, interaction risk). Exercise and slow-wave sleep restoration strengthen descending inhibition.

Enteric serotonin

Function: enterochromaffin cells release serotonin in response to luminal stimuli (short-chain fatty acids, bile acids, mechanical stretch, microbial metabolites), driving peristalsis via 5-HT4 on enteric neurons, secretion, and vagal afferent signaling of nausea via 5-HT3.

  • Hyperfunction: diarrhea, cramping, nausea (early SSRI effect; carcinoid syndrome with flushing and right-sided valvular disease; post-infectious IBS with increased enterochromaffin cells; SIBO-associated release).
  • Hypofunction: constipation, slow transit, functional dyspepsia.
  • Agents: ondansetron (5-HT3 antagonist; also reduces IBS-D symptoms), alosetron, prucalopride and tegaserod (5-HT4 agonists), SSRIs raise gut serotonin acutely. Spore-forming gut bacteria stimulate colonic TPH1 expression; the microbiome dimension is covered in the SIBO post here.

Platelets, vasculature, bone

Platelet serotonin (SERT uptake, no synthesis) is released during aggregation; SSRIs deplete it and raise bleeding risk modestly, more so with NSAIDs or anticoagulants. Triptans (5-HT1B/1D) constrict meningeal vessels and inhibit CGRP release. Circulating serotonin inhibits osteoblast proliferation via 5-HT1B; long-term SSRI use is associated with reduced bone density and fracture.

GABA and glutamate

Synthesis and clearance. Glutamate is produced from glutamine (glutaminase) and alpha-ketoglutarate; GABA from glutamate by glutamate decarboxylase (GAD65 and GAD67, PLP dependent, modulated by Mg2+ and Zn2+). GABA is cleared by GAT transporters and GABA transaminase (PLP). Glutamate is cleared by astrocytic EAAT2 and recycled through glutamine. Receptors: GABA-A (ionotropic Cl- channel; alpha-1 subunit mediates sedation and amnesia, alpha-2 and alpha-3 mediate anxiolysis and muscle relaxation, alpha-5 is hippocampal and affects memory; benzodiazepine, barbiturate, neurosteroid, ethanol, and flavonoid sites), GABA-B (metabotropic; baclofen, phenibut, GHB), NMDA (glutamate plus glycine or D-serine co-agonist, Mg2+ block, ketamine and memantine site), AMPA, kainate, metabotropic glutamate receptors (mGluR). Peripheral GABA is produced by pancreatic beta cells, the gut, and Lactobacillus and Bifidobacterium species; oral GABA does not cross the blood-brain barrier appreciably, though enteric and vagal effects are documented.

Cortex: excitation-inhibition balance

  • Hyper-GABA or hypo-glutamate: sedation, anterograde amnesia, psychomotor slowing, respiratory depression at extremes.
  • Hypo-GABA or hyper-glutamate: reduced seizure threshold, photophobia and phonophobia, migraine (cortical spreading depression), excitotoxicity in ischemia and neurodegeneration, hepatic encephalopathy involves both ammonia-driven glutamine accumulation and altered GABAergic tone.
  • Agents: valproate (GABA transaminase inhibition, sodium channel), vigabatrin (irreversible GABA-T inhibition), tiagabine (GAT-1), gabapentin and pregabalin (alpha-2-delta calcium channel subunit, reduced glutamate release), topiramate (multiple), levetiracetam (SV2A), lamotrigine (sodium channel, glutamate release), perampanel (AMPA antagonist). Nutritional: magnesium (voltage-dependent NMDA block; the best-supported nutrient for migraine prophylaxis and anxiety at 300 to 600 mg elemental), taurine (GABA-A and glycine receptor agonist, osmoregulation), glycine (strychnine-sensitive glycine receptors, NMDA co-agonist; 3 g at bedtime improves subjective sleep in small trials), L-theanine (modest GABA increase and glutamate antagonism; 200 to 400 mg), N-acetylcysteine (cystine-glutamate antiporter, restores extrasynaptic glutamate tone; trials in addiction and OCD). Ketamine and esketamine (NMDA antagonism with downstream AMPA-mediated BDNF and mTOR signaling) are approved for treatment-resistant depression under supervision; memantine (low-affinity NMDA antagonist) for dementia.

Amygdala and bed nucleus: anxiety and threat

  • Hypo-GABA: generalized anxiety, panic, hypervigilance, PTSD hyperarousal; benzodiazepine withdrawal and alcohol withdrawal are the clearest human models.
  • Hyper-GABA: disinhibition, emotional blunting, paradoxical aggression in some benzodiazepine users.
  • Agents: benzodiazepines (positive allosteric modulators across alpha subunits; tolerance and withdrawal with seizures after chronic use; 2 to 4 week limit in most guidance), Z-drugs (alpha-1 selective), neurosteroids (allopregnanolone, brexanolone, zuranolone approved for postpartum and major depression), SSRIs (via downstream effects), pregabalin (licensed for GAD in Europe). Plant-derived: kava (kavalactones; GABA-A modulation and sodium channel effects; multiple positive RCTs in GAD; hepatotoxicity signal, mainly with poor-quality extracts), apigenin (chamomile; weak benzodiazepine-site ligand; chamomile extract has a positive RCT in GAD; this site prefers it at night over quercetin because quercetin also inhibits COMT and MAO), lemon balm, passionflower, valerian (modest data). Phenibut (beta-phenyl-GABA; GABA-B agonist) produces tolerance, dependence, and a withdrawal syndrome comparable to benzodiazepines and is not recommended. Ethanol: GABA-A potentiation and NMDA inhibition, followed by rebound glutamate excess, which is the mechanism of withdrawal and of the early-morning awakening after evening alcohol described in the 3am post here.

Thalamus and reticular nucleus: sleep gating

GABAergic reticular neurons generate spindles and gate sensory transmission; the ventrolateral preoptic nucleus (VLPO) is the GABAergic sleep switch that inhibits histaminergic, orexinergic, and monoaminergic arousal centers.

  • Hypofunction: sleep-onset insomnia, sensory intrusion, light sleep.
  • Agents: Z-drugs, benzodiazepines, gabapentin (increases slow-wave sleep), dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant; act on the arousal side rather than GABA), melatonin and MT agonists (phase and VLPO facilitation), magnesium and glycine as above.

Spinal cord: tone, spasticity, pain

GABA and glycine mediate presynaptic and postsynaptic inhibition in the dorsal and ventral horn.

  • Hypofunction: spasticity, hyperreflexia, stiff-person syndrome (anti-GAD65 antibodies), neuropathic pain with loss of dorsal horn inhibition, tetanus and strychnine as toxic models.
  • Agents: baclofen (GABA-B; oral and intrathecal), tizanidine (alpha-2), diazepam, gabapentinoids, magnesium for cramps (evidence weak for idiopathic cramps, better in pregnancy and deficiency), glycine from collagen peptides as a dietary source.

Acetylcholine

Synthesis and clearance. Choline (dietary, or from phosphatidylcholine; de novo synthesis via PEMT is methylation-dependent) plus acetyl-CoA, by choline acetyltransferase (ChAT); choline uptake via the high-affinity transporter CHT1 is rate limiting. Cleared by acetylcholinesterase (AChE) and butyrylcholinesterase. Receptors: nicotinic (ionotropic; alpha-7 and alpha-4-beta-2 in brain, alpha-3-beta-4 at ganglia, alpha-1 at muscle) and muscarinic (M1 cortical cognition, M2 cardiac, M3 glands and smooth muscle, M4 striatal, M5). Cholinergic groups: basal forebrain (nucleus basalis of Meynert, medial septum, diagonal band; Ch1 to Ch4), brainstem (pedunculopontine and laterodorsal tegmental nuclei; Ch5 and Ch6), striatal interneurons, and the entire parasympathetic and somatic motor outflow.

Basal forebrain to cortex and hippocampus

Function: attention, cue detection, encoding of new memory, cortical plasticity, theta rhythm (medial septum).

  • Hypofunction: inattention, impaired encoding, delirium (anticholinergic delirium is the prototype), the cholinergic deficit of Alzheimer's disease and Lewy body dementia; cumulative anticholinergic burden (ACB score 3 or more) is associated with increased dementia incidence in several cohorts.
  • Hyperfunction: nausea, bradycardia, vivid dreams, cramps, and lacrimation with cholinesterase inhibitor excess; cholinergic tone is elevated in depression (the cholinergic-adrenergic hypothesis), with REM latency shortened.
  • Agents: donepezil, rivastigmine, galantamine (AChE inhibitors; galantamine also modulates nAChRs), huperzine A (reversible AChE inhibitor; Chinese trials in Alzheimer's with positive but low-quality signals), citicoline (CDP-choline; 500 to 2,000 mg; modest trial support in vascular cognitive impairment and stroke recovery), alpha-GPC (choline precursor; small trials in dementia), Bacopa monnieri (several RCTs showing modest memory benefit over 12 weeks; mechanism includes AChE inhibition and antioxidant effects), Hericium erinaceus (lion's mane; one positive RCT in mild cognitive impairment; NGF induction in vitro), nicotine (nAChR agonist; patch trials in MCI show attention benefit), and deprescribing of anticholinergics, which the medications table here lists.

Striatal cholinergic interneurons

Tonically active neurons modulating dopamine release and the D1/D2 balance; the pharmacologic basis of anticholinergic therapy for parkinsonism and dystonia (trihexyphenidyl), and of the cholinergic excess that follows D2 blockade.

Brainstem cholinergic nuclei (PPT and LDT)

Generate REM sleep and cortical activation with the thalamus; cholinergic agonists shorten REM latency, anticholinergics suppress REM. Involved in REM sleep behavior disorder and the gait and postural components of parkinsonian syndromes (PPT degeneration).

Parasympathetic outflow and the vagus

Function: M2-mediated bradycardia and reduced atrial contractility; M3-mediated salivation, lacrimation, bronchoconstriction, gastric acid and enzyme secretion, gut motility, detrusor contraction, pupillary constriction, and accommodation. The vagus also mediates the cholinergic anti-inflammatory pathway: efferent vagal signaling to the spleen suppresses macrophage TNF release via alpha-7 nAChR.

  • Hypofunction: dry mouth and eyes, gastroparesis, constipation, urinary retention, tachycardia, reduced heart rate variability; the autonomic neuropathy of diabetes, POTS, Sjögren's, and anticholinergic therapy (which is used deliberately for overactive bladder, sialorrhea, and IBS).
  • Hyperfunction: cholinergic crisis from organophosphates and nerve agents (SLUDGE: salivation, lacrimation, urination, defecation, GI distress, emesis; plus bronchorrhea, bradycardia, miosis, fasciculation); treated with atropine and pralidoxime.
  • Agents: bethanechol (M3 agonist) for urinary retention and gastroparesis, pilocarpine and cevimeline for Sjögren's, pyridostigmine (peripheral AChE inhibitor) for myasthenia and, off label, for POTS (raises ganglionic transmission; a small crossover trial reduced standing heart rate), atropine and glycopyrrolate as antagonists. Non-pharmacological vagal tone measures with measurable HRV effects: slow breathing at about six breaths per minute (four in, six out), cold facial immersion (diving reflex), and transcutaneous auricular vagus nerve stimulation (early trials in POTS, depression, and inflammatory disease). Implanted VNS is approved for epilepsy and depression; splenic and cervical VNS are in trials for rheumatoid arthritis and Crohn's. See the pots post here.

Neuromuscular junction

Alpha-1 nAChR at the motor endplate.

  • Hypofunction: myasthenia gravis (anti-AChR or anti-MuSK antibodies), Lambert-Eaton (presynaptic calcium channel antibodies), botulism (vesicle release blockade), neuromuscular blockers.
  • Hyperfunction: fasciculation and depolarizing block (succinylcholine), cholinesterase inhibitor excess.
  • Agents: pyridostigmine, neostigmine, immunotherapy for autoimmune disease, botulinum toxin therapeutically for dystonia, spasticity, and migraine.

Norepinephrine

Synthesis and clearance. Dopamine to norepinephrine by dopamine beta-hydroxylase (DBH; Cu2+ and ascorbate dependent, within synaptic vesicles); norepinephrine to epinephrine by PNMT (SAMe dependent) in the adrenal medulla. Cleared by NET (SLC6A2), MAO-A, and COMT. Central source is almost entirely the locus coeruleus (A6), with smaller medullary groups (A1, A2) regulating cardiovascular reflexes. Receptors: alpha-1 (vasoconstriction, arousal), alpha-2 (presynaptic autoreceptor inhibiting release; postsynaptic prefrontal enhancement; sedation at the LC), beta-1 (cardiac), beta-2 (bronchodilation, vasodilation, tremor, glycogenolysis), beta-3 (lipolysis, detrusor relaxation).

Locus coeruleus projections

Function: tonic arousal, vigilance, attention switching, stress response, memory consolidation of emotionally salient events, and modulation of pain gating.

  • Hyperfunction: anxiety, insomnia, hypervigilance, exaggerated startle, panic, PTSD nightmares; stimulant and SNRI excess; opioid withdrawal (LC disinhibition).
  • Hypofunction: hypoarousal, inattention, fatigue, impaired alerting; LC degeneration is early in Alzheimer's and Parkinson's disease.
  • Agents: atomoxetine and viloxazine (NET inhibition), SNRIs (venlafaxine, duloxetine, desvenlafaxine), stimulants, reboxetine, clonidine and guanfacine (alpha-2 agonists reducing LC output; approved for ADHD, used for tics, hypertension, opioid withdrawal, and PTSD), prazosin (alpha-1 antagonist for PTSD nightmares; mixed trial results), propranolol (beta blockade for performance anxiety, tremor, and reconsolidation research), lofexidine (alpha-2 for withdrawal).

Sympathetic postganglionic neurons

Function: vascular tone, heart rate and contractility, pupillary dilation, bronchodilation, renin release, lipolysis, glycogenolysis, sweating (cholinergic sympathetic fibers), piloerection.

  • Hyperfunction: hyperadrenergic POTS (standing plasma norepinephrine over 600 pg/mL), pheochromocytoma, thyrotoxicosis, stimulant toxicity, hypertensive crisis with MAOI plus tyramine or sympathomimetics, essential hypertension in part.
  • Hypofunction: neurogenic orthostatic hypotension (pure autonomic failure, multiple system atrophy, diabetic and amyloid neuropathy), neuropathic POTS with impaired lower-limb vasoconstriction, DBH deficiency (congenital; undetectable norepinephrine and epinephrine with elevated dopamine; droxidopa is the treatment), copper deficiency lowering DBH activity.
  • Agents: midodrine (alpha-1 prodrug), droxidopa (L-threo-DOPS, converted to norepinephrine by AADC), fludrocortisone (volume), pyridostigmine (ganglionic), ivabradine (sinus node If channel; heart rate without blood pressure effect, used in POTS), beta blockers, clonidine and methyldopa for hyperadrenergic phenotypes. Cofactors: copper (plasma copper and ceruloplasmin), ascorbate. The pots post here maps the subtypes to these mechanisms.

Histamine

Synthesized from histidine by histidine decarboxylase (PLP dependent); central source is the tuberomammillary nucleus (TMN) of the posterior hypothalamus, which fires only during wakefulness and is silenced by VLPO GABA at sleep onset; peripheral sources are mast cells, basophils, enterochromaffin-like cells, and gut bacteria. Cleared centrally by HNMT (SAMe dependent) and peripherally by DAO (AOC1; copper and PLP dependent). Receptors: H1 (wakefulness, itch, vascular permeability), H2 (gastric acid, cardiac, some CNS), H3 (presynaptic autoreceptor and heteroreceptor inhibiting histamine, acetylcholine, norepinephrine, and dopamine release), H4 (immune cells).

  • Hyperfunction (central): insomnia with early-morning awakening, anxiety, pruritus; (peripheral): the mast cell activation picture.
  • Hypofunction (central): sedation and cognitive slowing from brain-penetrant H1 antagonists (diphenhydramine, hydroxyzine, doxepin, chlorpheniramine, promethazine, and the H1 component of mirtazapine, quetiapine, olanzapine); cumulative exposure is part of the anticholinergic-and-antihistaminergic dementia association.
  • Agents: second-generation H1 antagonists with limited CNS penetration (fexofenadine, loratadine, cetirizine at standard doses), H2 antagonists (famotidine), pitolisant (H3 inverse agonist raising central histamine; approved for narcolepsy), ketotifen and cromolyn (mast cell stabilization), methylation support for HNMT and copper and PLP for DAO. The 3am post here and the mast cell post here cover the clinical reasoning.

Cofactors, precursors, and the shared pipeline

Transmitter Precursor Rate-limiting enzyme and cofactors Clearance and cofactors Nutritional levers with evidence
Dopamine L-tyrosine TH: Fe2+, BH4 (folate, NADH, DHPR, GCH1) COMT: SAMe, Mg2+; MAO-B: FAD; DAT Iron to ferritin over 75 in RLS (A); tyrosine 100 to 150 mg/kg acutely for cognitive performance under stress (B); mucuna in PD (B, short term); riboflavin for MAO and MTHFR (B)
Norepinephrine Dopamine DBH: Cu2+, ascorbate COMT, MAO-A, NET Copper repletion when deficient (B); vitamin C status (C)
Serotonin L-tryptophan TPH2: Fe2+, BH4; AADC: PLP SERT; MAO-A: FAD Tryptophan 1 to 3 g or 5-HTP 50 to 300 mg (B, with interaction caution); B6 as P5P (B when deficient); carbohydrate for LAT1 entry (B); bright light (A for SAD)
GABA Glutamate GAD65/67: PLP, Mg2+, Zn2+ GABA-T: PLP; GAT Magnesium 300 to 600 mg (A for migraine prophylaxis, B for anxiety); taurine 1 to 3 g (C); glycine 3 g at night (B for sleep quality); theanine 200 to 400 mg (B for acute stress)
Glutamate Glutamine, alpha-KG Glutaminase; transaminases EAAT2 (astrocytes) NAC 1.2 to 2.4 g for glutamate homeostasis (B in addiction and OCD); magnesium for NMDA block (A to B)
Acetylcholine Choline, acetyl-CoA ChAT; CHT1 uptake; pantothenate for CoA AChE, BuChE Choline 425 to 550 mg daily intake (A for adequacy); citicoline 500 to 2,000 mg (B); alpha-GPC (C); huperzine A 200 to 400 mcg (B, low quality)
Histamine L-histidine HDC: PLP HNMT: SAMe; DAO: Cu2+, PLP DAO supplementation with meals (B in histamine intolerance); copper and B6 when deficient (C); methylation support (C)

Transporter competition. Tyrosine, tryptophan, phenylalanine, leucine, isoleucine, valine, methionine, and histidine share LAT1 at the blood-brain barrier. Precursor loading of one lowers brain entry of the others; chronic 5-HTP monotherapy depletes catecholamines in animal models and tyrosine monotherapy lowers serotonin synthesis. Protein meals raise plasma LNAAs and reduce tryptophan entry; carbohydrate meals do the opposite through insulin.

BH4 as the common bottleneck. TH, TPH, and nitric oxide synthase all require tetrahydrobiopterin. BH4 is synthesized de novo via GCH1 (inflammation-inducible) and regenerated via DHPR using NADH; oxidative stress oxidizes BH4 to BH2, uncoupling NOS and starving the monoamine hydroxylases. Folate (as 5-MTHF) supports DHPR-independent regeneration of BH4 from BH2 in some models, which is the mechanism proposed for the rapid mood and catecholamine effects of methylfolate observed clinically in people whose methylation is stretched, and for the over-stimulation that COMT Met/Met carriers can experience with the same intervention. The methylation here report covers MTHFR, MTR, MTRR, and the folate transporters; the neurotransmitters here report covers GCH1, QDPR, TH, TPH2, COMT, MAOA, MAOB, DBH, DDC, SLC6A4, DRD2, DRD4, GAD1, and HNMT.

Iron. TH and TPH are Fe2+ enzymes; brain iron is actively transported and lags serum repletion by months. The ferritin post here sets targets.

Combination hazards worth naming

  • Serotonin syndrome: SSRI or SNRI with MAOI, linezolid, methylene blue, tramadol, meperidine, dextromethorphan, lithium, triptans (low risk), 5-HTP, tryptophan, St. John's wort.
  • Hypertensive crisis: MAOI with tyramine-rich food, sympathomimetics, L-DOPA, or high-dose tyrosine.
  • Additive CNS depression and respiratory depression: benzodiazepines or Z-drugs with opioids, alcohol, gabapentinoids, phenibut, kava.
  • Anticholinergic burden: additive effects of antihistamines, tricyclics, bladder antimuscarinics, antipsychotics, and antispasmodics on cognition and delirium risk.
  • Dopaminergic excess: L-DOPA or agonists with stimulants or bupropion; impulse-control disorders and psychosis.
  • Hyperprolactinemia: D2 antagonists with metoclopramide or domperidone.

Experimental and emerging agents, with their evidence

Agent System Status
Ketamine and esketamine NMDA antagonism, AMPA and BDNF downstream Esketamine FDA approved (2019) for treatment-resistant depression; IV ketamine widely used off label with multiple RCTs
Psilocybin 5-HT2A agonism, network-level plasticity Phase 2 and 3 trials in MDD and TRD; breakthrough therapy designation; regulated access in Oregon and Australia
Zuranolone, brexanolone GABA-A neurosteroid site FDA approved for postpartum depression; zuranolone also for MDD
Dual orexin receptor antagonists Arousal side of the sleep switch Approved for insomnia
Pitolisant H3 inverse agonism Approved for narcolepsy; trials in other hypersomnias
Transcutaneous auricular VNS Cholinergic anti-inflammatory pathway Early RCTs in depression, POTS, and inflammatory disease
Xanomeline-trospium M1/M4 agonism without D2 blockade FDA approved (2024) for schizophrenia; the first non-dopaminergic antipsychotic
Phenibut GABA-B No regulated trials; dependence and withdrawal syndrome; not recommended
Bromantane, racetams, peptide "nootropics" Various claimed Russian or animal data only; not evaluable

Markers that test the model

Urinary organic acids (homovanillic acid, vanillylmandelic acid, 5-hydroxyindoleacetic acid, kynurenate and quinolinate for the IDO diversion), plasma amino acids (tyrosine, tryptophan, phenylalanine, glutamine, glutamate, glycine, taurine), ferritin with saturation and CRP, copper and ceruloplasmin, plasma or whole-blood B6 (PLP), RBC magnesium, homocysteine and RBC folate for methylation status, standing versus supine plasma catecholamines where POTS is in question, prolactin where D2 blockade is in question, and HRV as the accessible index of vagal tone. The lab guide here carries assay notes and functional intervals. Urinary neurotransmitter panels marketed to consumers measure peripheral excretion and do not reflect central tone; they are not used here.

Educational and research content, not medical advice. The author holds a PhD in cellular and molecular nutrition, is not a licensed physician, and does not diagnose, treat, cure, or prevent disease. Medication initiation, dose, and combination are decisions of the prescribing clinician; the interactions listed above carry serious risk.